On November 24, 2025 Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, reported that a second scientific abstract from its research and development programs was presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting, which took place November 19-23 in Honolulu, Hawaii.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster titled "Discovery and development of novel CNS-penetrating PARP1-selective inhibitors," was developed in collaboration with investigators at the Vancouver Prostate Centre and the University of British Columbia, describes the Company’s work applying artificial-intelligence (AI) methods to the discovery and early characterization of novel, PARP1-selective small-molecule drug candidates with properties consistent with central nervous system (CNS) penetration.
The presentation outlines the use of Deep Docking and generative-AI computational approaches to virtually screen large chemical libraries and identify compounds predicted to demonstrate selective inhibition of PARP1, favourable drug-like properties, and characteristics supportive of CNS exposure.
According to the data reported, hundreds of prioritized compounds have been synthesized and evaluated in biochemical assays. A subset demonstrated PARP1-selective activity, as well as in vitro metabolic-stability and pharmacokinetic profiles that will inform additional optimization and testing. Examples of ADME and pharmacokinetic data from the first round of synthesized compounds, including comparisons with existing PARP inhibitors and next-generation benchmark compounds, were also presented.
Prof. Mads Daugaard, President of Rakovina Therapeutics, commented: "The data generated to date provide early insight into our AI-driven discovery platform and its ability to prioritize compounds with the features we are seeking, including PARP1 selectivity and properties supportive of CNS penetration. These results demonstrate timely progress of our PARP1-selective inhibitor program and validate our iterative AI approach."
This SNO 2025 presentation represents the second abstract from Rakovina Therapeutics at the conference and reflects the Company’s ongoing research efforts in the field of DNA-damage-response (DDR) therapeutics.
(Press release, Rakovina Therapeutics, NOV 24, 2025, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-inc-announces-presentation-of-second-abstract-at-the-2025-society-for-neuro-oncology-annual-meeting [SID1234660907])